Treatment of Acquired Long QT Syndrome in LQT3 with SCN5A Pathogenic Mutation and Prolonged QT Interval

This protocol covers patients with Long QT syndrome type 3 (LQT3) harbouring a pathogenic SCN5A mutation who present with a prolonged QT interval — a genotype-defined scenario that warrants a targeted management strategy distinct from other LQTS subtypes.

Clinical Scenario

The patient carries a confirmed SCN5A pathogenic mutation consistent with Long QT syndrome type 3, and has a documented prolonged QT interval on 12-lead ECG. This genotype-specific presentation guides both risk stratification and the choice of therapy.

Treatment Approach (Partial Overview)

Management combines general protective measures with genotype-directed pharmacological therapy. One agent in this protocol has specific evidence in LQT3 patients with a prolonged QT interval.

The complete regimen — drug selection, sequencing, and response criteria — is available in the full structured protocol.

Treatment Goal

The key therapeutic target is a meaningful shortening of the QTc interval confirmed on oral testing, used to verify suitability before committing to long-term treatment.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/eurheartj/ehac262

Mexiletine is indicated in LQT3 patients with a prolonged QT interval.
Beta-blockers, ideally non-selective beta-blockers (nadolol or propranolol), are recommended in LQTS patients with documented QT interval prolongation, to reduce risk of arrhythmic events.
Avoid QT-prolonging drugs.
Avoid and correct electrolyte abnormalities.
Avoid genotype-specific triggers for arrhythmias.
It is advisable to perform oral testing to verify that the QTc shortens 40 ms before prescribing chronic treatment.

View source ↗